Duvelisib (IPI-145) is an oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ in clinical development for the treatment of hematologic malignancies, including indolent non-Hodgkin lymphoma (iNHL). In a Phase 1, open-label study to determine the maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, clinical activity, and safety of duvelisib monotherapy in patients with advanced hematologic malignancies, duvelisib was administered at eight dose levels (8-100 mg BID) in a dose-escalation phase (n = 31 evaluable patients). Two doselimiting toxicities (DLTs), Grade 3 transaminase elevations and Grade 3 rash, occurred at 100 mg BID, and the MTD was determined to be 75 mg BID. Across all doses, 58.1% of iNHL patients had a response (19.4% complete, 35.5% partial, and 3.2% minor); median time to response was 1.84 months and duration of response was 16.9 months. Median progression-free survival was 14.7 months, and the probability of overall survival at 24 months was 71.7%.
| INTRODUCTION
Non-Hodgkin lymphoma (NHL) is a heterogenous group of lymphoid malignancies with clinical behaviors ranging from indolent (iNHL) to aggressive. iNHL accounts for approximately 40% of all NHL cases, and includes follicular lymphoma (FL) and marginal zone lymphoma (MZL) . Approximately 71 000 and 93 500 new cases of NHL are diagnosed each year in the U.S. and Europe, respectively, with almost 19 000 and 38 000 persons dying from these diseases annually. 1, 2 Standard treatments for iNHL include monoclonal antibodies (eg, anti-CD20) often in combination with chemotherapy (chemoimmunotherapy, CIT), radioimmunotherapy (RIT), and external-beam radiotherapy. While frontline treatment of advanced iNHL patients with CIT-based regimens induces overall response rates (ORRs) of 90% or higher, 3 eventual relapse is expected, with response rates and durations decreasing with each successive line of therapy. Although median survival with current therapies is estimated at greater than 10 years for newly diagnosed patients, iNHL remains incurable, necessitating the development of new effective oral treatments with novel mechanisms of action and acceptable toxicity profiles.
Phosphoinositide 3-kinase (PI3K) is a lipid kinase involved in intracellular signal transduction. PI3K's catalytic subunit (p110) exists in four isoforms: α, β, δ, γ. While α and β isoforms are virtually ubiquitous, δ and γ isoforms are preferentially expressed in leukocytes and play an important role in adaptive and innate immune responses in Bcell, T-cell, and myeloid cell function [4] [5] [6] [7] PI3K-δ inhibition includes multiple key effects on malignant B-cells, including blockade of tumor microenvironment-mediated malignant B-cell proliferation and migration, and inhibition of tumor cell-derived chemokine secretion. [8] [9] [10] In addition, PI3K-γ inhibition is believed to block the formation of the tumor microenvironment through inhibition of T-cell and macrophage migration towards microenvironment-derived chemokines, and to block macrophage polarization to a tumor-supporting M2 phenotype. 8, [11] [12] [13] In transformed FL xenograft models, combined inhibition of PI3K-δ and PI3K-γ enhanced tumor-growth suppression compared to inhibition of either isoform alone, 14 suggesting complementary dual isoform contributions to tumor growth and survival.
Accordingly, when compared with PI3K-δ inhibition alone, dual PI3K-δ,γ inhibition may enhance therapeutic benefit in patients with lymphoid malignancies.
The expanding recognition of PI3K-δ and PI3K-γ's roles in hematologic malignancies has triggered the recent development of classspecific inhibitors of PI3K for use as anticancer agents. Idelalisib, an oral inhibitor of PI3K-δ only, is approved for treatment in iNHL and in relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab. Duvelisib (also known as IPI-145) 15 is an oral dual inhibitor of both PI3K-δ and PI3K-γ that has demonstrated selective antiproliferative activity against leukemia cells in vitro while sparing normal lymphoid cells. 9, 16, 17 Here we report on the efficacy, safety, and pharmacodynamic activity of duvelisib in patients with relapsed/refractory iNHL based on results from the first clinical study of duvelisib in patients with advanced hematologic malignancies.
| PATIENTS AND METHODS

| Study design and treatment
Study IPI-145-02 was a Phase 1, open-label, dose-escalation study in patients with advanced hematologic malignancies. Duvelisib was administered as oral capsules twice daily (BID) continuously in 28-day cycles until disease progression or unacceptable toxicity. Dose interruptions and dose reductions (up to 2) were allowed in the event of duvelisib-related toxicities. Clinic visits occurred weekly during the first three treatment cycles, biweekly during Cycles 4 and 5, monthly during Cycles 6 through 19, and once every third cycle thereafter.
During the expansion phase, patients with certain hematologic malignancies, including iNHL, were treated with either the MTD (75 mg BID) or 25 mg BID. The rationale for selecting the latter dose for expansion was based on the review of preliminary data collected during the dose escalation phase (DEP), including safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity. 18 All patients provided informed consent before undergoing any study procedure. The protocol was approved by site Institutional
Review Boards, and the study was conducted according to local and federal regulations and the Declaration of Helsinki.
| Patients and eligibility criteria
Patient enrollment criteria included age ≥ 18 years, life expectancy >3 months, and a diagnosis of advanced hematologic malignancy.
Patients were also required to have progressed on, been refractory to, Table S1 ). The PD analysis set consisted of all iNHL patients for whom at least the C1D1 sample and one other sample at C1D8, C2D1, or C3D1 were available. 
| Efficacy assessments
| Safety assessments
Adverse event (AE) monitoring and laboratory assessments were performed at all clinic visits. AEs were graded using the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Summaries include all iNHL patients who received at least one dose of duvelisib. At the time of this analysis, two patients remained on duvelisib 25 mg BID and 29 had discontinued treatment.
| Statistical methods
| Duvelisib pharmacodynamics in iNHL
In an exploratory analysis, a group of 74 serum factors, including chemokines, cytokines, matrix metalloproteinases, and other proteins were evaluated (Supporting Information Table S1 ). These factors were chosen because of their relevance to the tumor microenvironment in supporting malignant B cells, including cell-migration, cell-cell associations, cell-proliferative, and differentiation functions. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Pharmacodynamic data were available from 9 to 24 iNHL patients, depending on the analyte and time point; 10 of the 74 serum analytes tested decreased significantly from baseline at C1D8: CCL1, CCL4, CCL17, CCL22, CXCL10, CXCL13, IL-10, IL-16, MMP-9, and
TNFα. (Supporting Information Table S2 and Figure S1 ). Three of the 10 analytes (CCL17, CXCL13, and MMP-9) also exhibited a significant change at C2D2. No analyte increased significantly from baseline.
With the exception of CXCL10, each of the analytes noted above was elevated at baseline in serum from iNHL patients when compared with serum from healthy donors (n = 33). After 8 days of duvelisib treatment, the levels of five of the analytes elevated at baseline were Figure S2 ).
Among all iNHL patients who had a response (n = 18), the median TTR was approximately 1.8 months across doses (range 1.5-4.1) and for the 25 mg and 75 mg BID dose groups. The median DOR was 16.9 months across doses, 12.9 months for the 25 mg BID group (n = 9), and 16.9 months for the 75 mg BID group (n = 7). The estimated probability of remaining in response at 6, 12, and 18 months was 76.6%, 67.0%, and 44.7%, respectively, across dose groups (Supporting Information Figure S3 ).
Across doses, 11 (35.5%) patients progressed and 2 (6.5%) died of other causes. Median PFS was 14.7 months for all doses, 14.7 months for the 25 mg BID group, and 5.5 months for the 75 mg BID group (Figure 1 ). The estimated probability of being progression free at 6, 12, and 18 months was 65.0%, 58.5%, and 48.8%, respectively, across doses (Figure 1 ).
For the overall survival analysis, 21 (67.7%) patients across doses were censored, which included patients who were either alive and in follow-up at the time of this analysis, alive after having completed the 2-year survival follow-up, or were lost to follow-up at the time of the data analysis. The median time of OS was not reached. The estimated probability of survival at 6, 12, and 18 months was 86.1%, 78.9%, and 75.3% (Supporting Information Figure S4 
| Safety
The most frequently reported (>15% patients) all-causality treatmentemergent AEs and investigation abnormalities in iNHL patients treated with duvelisib are presented in Table 3 . Most events were grades 1-2 with a few exceptions. Transaminase elevations and diarrhea were the most frequent nonhematologic AEs (both 54.8%) and the most common recognized as the standard treatment approach for iNHL. 31 However, 
